Auven Therapeutics
475 NE 1st St Ste A, Delray Beach, Florida, 33483, United States
Overview
Auven Therapeutics is a private equity company focused on the healthcare industry. The Company’s strategy is to acquire controlling ownership in promising therapeutic products or platforms. The value of these therapeutic assets is then significantly enhanced by global development programs prior to selling them as clinically and commercially validated products to established pharmaceutical companies. Auven Therapeutics has built a diversified portfolio of biologic and small molecule therapeutic candidates for a wide range of therapeutic indications. The Company’s existing pipeline addresses critical unmet medical needs in cancer, ophthalmic conditions, women’s health and orphan diseases. It has ownership of or a controlling interest in the therapeutic assets of ADC Therapeutics, Spirogen, Resolvyx and Kiacta, and a minority investment in Kolltan and Sprout Pharmaceuticals. Founded in 2007 by industry veterans Stephen Evans-Freke and Dr. Peter B. Corr, Auven Therapeutics Management L.L.L.P. is an investment advisor with its principal place of business in the US Virgin Islands. It manages Auven Therapeutics Holdings L.P., a private equity fund, which has its registered office and principal place of business in the British Virgin Islands. Auven Therapeutics Development, the operating company of Auven Therapeutics Holdings L.P. manages drug development from its bases in Lausanne, Switzerland, New York, USA and Hamilton, Bermuda. Auven Therapeutics is an investment advisor with its principal place of business in the US Virgin Islands. It manages Auven Therapeutics Holdings L.P., a private equity fund, which has its registered office and principal place of business in the British Virgin Islands. Auven Therapeutics Development, the operating company of Auven Therapeutics Management L.L.L.P. Holdings L.P. manages drug development from its bases in Lausanne, Switzerland, New York, USA and Hamilton, Bermuda.
- Total investments
- 5
- Lead investments
- 3
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Advice
- Health Care
- Therapeutics
Investment portfolio
- ADC Therapeutics
Led · Equity · Oct 2017
ADC Therapeutics develops and commercializes antibody–drug conjugates (ADCs) targeting difficult-to-treat hematologic malignancies, with its lead product ZYNLONTA already approved in the United States and Europe for adults with relapsed or refractory large B-cell lymphoma after at least two prior systemic therapies. The company is advancing additional studies including the LOTIS-5 and LOTIS-7 trials to expand ZYNLONTA’s label, aiming for full enrollment of 100 patients in LOTIS-7 by H1 2026 and additional data in H2 2025. Management is preparing for a potential relaunch of ZYNLONTA in 2027 and intends to invest in commercial expansion to support that goal. Preliminary Q3 revenues from ZYNLONTA were approximately $15.8 million. Prior to the new financing, cash and cash equivalents totaled $234.7 million as of 30 September 2025, and are expected to rise to about $292.3 million after the transaction. The company’s free cash flow was negative $128 million over the last twelve months, underscoring the importance of fresh capital. Shares have risen roughly 262 % in the past six months, trading near a 52-week high of $4.74.
- Kolltan Pharmaceuticals
Led · Series B · Jan 2010
Kolltan Pharmaceuticals is a New Haven, CT–based biopharmaceutical company focused on discovering and developing novel biologic agents designed to modulate receptor tyrosine kinases (RTKs). Its lead clinical-stage candidate, KTN3379, is a dual-mechanism monoclonal antibody that potently inhibits the ErbB3 RTK. The company intends to use the Series D proceeds to advance KTN3379 into Phase 2 clinical trials in cancer patients with various malignancies. Kolltan also plans to advance its preclinical candidates toward IND filing and clinical studies. Management is led by President and CEO Jerry McMahon, Ph.D., with Arthur Altschul, Jr. as Chairman. The company completed a $60M Series D to fund these development efforts. Kolltan Pharmaceuticals is developing a new generation of monoclonal antibody oncology therapeutics based on seminal discoveries from the laboratory of Dr. Joseph Schlessinger at the Yale School of Medicine. The company is advancing multiple therapeutic candidates in its pipeline and intends to use new funding to progress development. In January 2010 Kolltan closed a $10m Series B financing to support those efforts. The Series B consists of $8.5m in Series B convertible preferred stock and $1.5m that can be applied to a product development option or converted into Series B convertible preferred stock. Kolltan is based in New Haven, CT and previously completed a $40m Series A in which current investors also participated.
Team
No current team members are available.